engleski

CD34 in acute leukemia

Subtypes of acute leukemia (AL) are classified according to clinical and cytomorphological, cytochemical, immunological, cytogenetic and molecular characteristics of leukemic cells. The immunoexpression of CD34 molecule is mostly related to some types of myeloid AL (M0, M1 and M2) and B-acute lymphoid leukemia and is also associated to inferior response to cytostatic therapy and shorter disease free survival. Immunophenotyping, as cytogenetic and molecular analysis, is also important in AL minimal residual disease (MRD) detection mostly by recognizing uncommon antigen combinations (i.e. CD34/CD11b, CD13/CD2). Analysis of higher expression of only one antigen, such as CD34 expressed on immature hematopoietic cells, can only indicate the presence of MRD. Aim of the study was to analyze CD34 of bone marrow (BM) hematopoietic cells (HC) in CD34+ AL patients before and after cytostatic therapy. Methods: CD34 was analyzed by flow-cytometry and after immunocytochemical APAAP staining in 19 patients with CD34+AL and in 10 healthy BM donors. Results: The percentages of CD34+ BM HCs in 14 AL patients with remission (median 4%) were significantly lower than before therapy (median 55%) and also were lower than in 5 AL patients without remission (median 25%) (p< 0.05). Also, the percentages of CD34+ BM HCs in 14 AL patients with remission were not significantly different in comparison to the control group of 10 healthy BM donors. Conclusion: Results of the study point that lower percentage of BM CD34+ HCs in patients with CD34+ AL after cytostatic therapy is indicator of remission of disease

CD34; acute leukemia; flow cytometry; immunocytochemistry

nije evidentirano